Publications

February 2015 (Revised November 2015)
Case

Building an Integrated Biopharma Company: Crucell (A)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling

By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Biotechnology Industry; Pharmaceutical Industry; Netherlands

Educators

01 Mar 2007
News

Daniel Vasella

sales of $37 billion. The company’s aggressive investment in research has made it an industry leader in new drug approvals. And when opportunity knocks, Vasella doesn’t hesitate to broaden Novartis’s business mix through acquisitions. He recently added generic drugs... View Details

Keywords: Roger Thompson; multinational pharmaceutical company; prescription drugs; vaccines; Medicare; generics business; Health, Social Assistance

February 2023
Article

Maintaining Health Care Innovations After the Pandemic

By: Regina E. Herzlinger, Barak D. Richman and Kevin A. Schulman

The COVID-19 pandemic exposed the worst failings of the health care system, but it also stimulated a flurry of innovations that could lead to a much-improved delivery system. These were innovations that were born out of necessity: telemedicine access and use... View Details

Keywords: Health Care; Health Care Industry; Health Care Outcomes; Innovation; Innovation In Healthcare Delivery; COVID; COVID-19 Pandemic; Pandemics; Telemedicine; Telehealth; Ambulatory Care; Vaccines; Innovation and Invention; Change; Health Industry

2022
Editorial

It’s Time to Redouble and Refocus Our Efforts to Fight COVID, Not Retreat

By: Kathleen Bachynski, Brian C. Castrucci, Esther K. Choo, Ranu Dhillon, Jim Downs, Lakshmi Ganapathi, Gregg Gonsalves, Abraar Karan, Richard C. Keller, Scott Duke Kominers, Jonathan Levy, Martha Lincoln, Seth Prins, Julia Raifman and Anne Sosin

Keywords: COVID; COVID-19; COVID-19 Pandemic; Public Health; Public Health Measures; Vaccination; Health Policy; Health Pandemics; Government and Politics; United States

February 2015 (Revised November 2015)
Supplement

Building an Integrated Biopharma Company: Crucell (B)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling

The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Pharmaceutical Industry

April 2022
Teaching Note

CVS Health: Prescription for Transformation

By: Rosabeth Moss Kanter and Catarina Martinez

In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant). The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a... View Details

Keywords: Health; COVID-19 Pandemic; Primary Care; Leadership; Change Management; Women Executives; Retail; Pharmacy; Pharmacy Benefit Manager; Clinical Trials; Vaccination; Acquisition; Innovation and Invention; Transformation; Retail Industry; Pharmaceutical Industry; Health Industry; United States

28 Sep 2021
News

World Can Have Covid Boosters and Its First Doses, Too

15 Dec 2021
Research & Ideas

The 10 Most Popular Articles of 2021

Many people began 2021 with optimism, hopeful that a COVID-19 vaccine would be widely available within months. Surely the pandemic would end soon, right? It was, perhaps, a naïve thought in a pandemic-weary world. Nevertheless, companies... View Details

Keywords: by Danielle Kost

15 Jul 2020
News

Coronavirus could be ‘under control’ in weeks if everyone wore masks, CDC director says

March 2023
Case

Moderna

By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb

This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details

Keywords: Health Pandemics; Research and Development; Digital Transformation; Health Testing and Trials; Biotechnology Industry; Pharmaceutical Industry

Educators

29 Jun 2020
News

After saving his own life with a repurposed drug, a professor reviews every drug being tried against Covid-19. Here's what he's found

05 Oct 2016
Research & Ideas

Why Don't More People Get Flu Shots at Work?

With a yearly price tag of roughly $87 billion in lost productivity and adverse health consequences, the flu is nothing to sneeze at. It’s no surprise that workplace flu vaccination clinics have gained popularity as employers try to keep... View Details

Keywords: by Roberta Holland; Health

January 2025 (Revised March 2025)
Case

Gavi and the 'Next' Pandemic

By: Tarun Khanna and Kerry Herman

In 2025, CEO Dr. Sania Nishtar and her team consider the lessons the Global Alliance for Vaccine and Immunizations (GAVI) learned from the pandemic. GAVI successfully brought COVID-19 vaccines to large swaths of the undeveloped and under-developed world by pooling... View Details

Keywords: Developing Countries and Economies; Health Care and Treatment; Health Pandemics; Crisis Management; Success; Innovation and Invention; Service Delivery; Organizational Change and Adaptation; Strategic Planning; Pharmaceutical Industry; Africa

Educators

23 Jun 2021
News

Biden Is Rushing America’s Return to Normalcy

25 Jul 2020
News

Don't hold your breath for a coronavirus vaccine. Here are 7 big challenges we need to overcome

August 2017
Article

Should Governments Invest More in Nudging?

By: Shlomo Benartzi, John Beshears, Katherine L. Milkman, Cass R. Sunstein, Richard H. Thaler, Maya Shankar, Will Tucker-Ray, William J. Congdon and Steven Galing

Governments are increasingly adopting behavioral science techniques for changing individual behavior in pursuit of policy objectives. The types of “nudge” interventions that governments are now adopting alter people’s decisions without coercion or significant changes... View Details

Find at Harvard